Becton, Dickinson and Company BDX, popularly known as BD, is evaluating the divestment of its Life Sciences division as part ...

Becton, Dickinson and Co. also reported slightly higher pay for the device developer and manufacturer's median worker in ...

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2024 ...

The solution enables the use of BD's Synapsis informatics with BD Phoenix M50 automated microbiology and rapid identification and AST on the BDXpert system.

Becton Dickinson & Co. closed 20.98% short of its 52-week high of $251.99, which the company reached on February 3rd.

Buy rating initiated! Discover why this medtech leader with strong growth prospects & dividends is worth your attention.

Barclays lowered the firm’s price target on Becton Dickinson (BDX) to $261 from $279 and keeps an Overweight rating on the shares. The firm ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Fortune's 2025 list of America's Most Innovative Companies, ranking in the top 25% of ...

This was the stock's third consecutive day of losses.

The Financial Times reports today that BD (NYSE: BDX) began discussions with competitors for the sale of its Life Sciences ...

In February the company had announced its plan to separate the unit, which consists of biosciences and diagnostic solutions, ...